ANI Pharmaceuticals (NasdaqGM:ANIP) FY Conference Transcript

ANI Pharmaceuticals FY Conference Summary Company Overview - Company: ANI Pharmaceuticals (NasdaqGM:ANIP) - Focus: Transitioning from a generics company to a leading rare disease company, with over 50% of revenues now derived from rare disease assets [3][6] Key Financial Highlights - 2025 Performance: - Revenue growth of 44% year-over-year - Adjusted non-GAAP EBITDA growth of 47% - Rare disease business revenue: $347 million, a growth of 75%-76% - Generics business revenue: $384 million, a growth of 28% [6][7] - 2026 Guidance: - Projected total company revenues: $1 billion to $1.115 billion - Projected adjusted non-GAAP EBITDA: $275 million to $290 million - Rare disease revenue expected to grow to $540 million to $575 million [7][8] Core Product Insights - Cortrophin: - Addressable patient population for acute gouty arthritis flares: 285,000 patients, with only 36% receiving treatment and 8% receiving injectable treatments [12] - Market growth potential is significant, with a focus on underpenetrated indications [12][13] - The ACTH market was valued at $1.2 billion in 2017 but declined to $600 million in 2021 due to external factors. The market is now recovering [27][28] - ILUVIEN: - Acquired to synergize with Cortrophin, focusing on ophthalmology - Expanded sales force to promote both Cortrophin and ILUVIEN [51] - Indicated for diabetic macular edema and chronic non-infectious uveitis, with a simplified product label [53] Competitive Landscape - Cortrophin vs. Competitors: - Difficult to genericize due to complex manufacturing processes and formulation differences [16][38] - ANI's growth has been driven by reaching new patients rather than just capturing market share from competitors [33] Strategic Focus - Investment in R&D: ANI invests a high single-digit percentage of generics sales into R&D, allowing for the launch of 10-15 new products annually [61] - Balance Sheet: Leverage reduced to 2x, with a focus on organic growth opportunities in rare disease and generics [75] Market Perception and Investor Feedback - There is a perceived disconnect between stock performance and the company's growth potential, particularly in the rare disease segment [79][82] - The company emphasizes the long-term growth potential of its rare disease portfolio and the durability of its assets [82] Conclusion - ANI Pharmaceuticals is positioned for significant growth in the rare disease market, with strong financial performance in 2025 and optimistic guidance for 2026. The company is focused on expanding its market presence while maintaining profitability and addressing investor concerns regarding the durability of its growth.